1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK

CDK

Cyclin dependent kinase

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-117677
    Cdc7-IN-21
    Inhibitor
    Cdc7-IN-21 (compound 10c) is a potent and selective Cdc7 inhibitor with an IC50 of 0.07 nM. Cdc7-IN-21 can be used to study cancer.
    Cdc7-IN-21
  • HY-147409
    Ulecaciclib
    Inhibitor
    Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics.
    Ulecaciclib
  • HY-161463
    CDK2-IN-28
    Inhibitor
    CDK2-IN-28 (compound 22) is a CDK2 inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 μM).
    CDK2-IN-28
  • HY-155844
    CDK9-IN-26
    Inhibitor
    CDK9-IN-26 (compound 1is a CDK9 inhibitor (IC50=0.18 μM). .
    CDK9-IN-26
  • HY-RS02403
    Cdk9 Rat Pre-designed siRNA Set A
    Inhibitor

    Cdk9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk9 Rat Pre-designed siRNA Set A
    Cdk9 Rat Pre-designed siRNA Set A
  • HY-RS02386
    Cdk5 Rat Pre-designed siRNA Set A
    Inhibitor

    Cdk5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk5 Rat Pre-designed siRNA Set A
    Cdk5 Rat Pre-designed siRNA Set A
  • HY-173007
    ALK/PI3K/AKT-IN-1
    Inhibitor
    ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC50 of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids.
    ALK/PI3K/AKT-IN-1
  • HY-RS02400
    Cdk8 Rat Pre-designed siRNA Set A
    Inhibitor

    Cdk8 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk8 Rat Pre-designed siRNA Set A
    Cdk8 Rat Pre-designed siRNA Set A
  • HY-18629A
    (E/Z)-SU9516
    Inhibitor
    (E/Z)-SU9516 is the isomer of SU9516 (HY-18629). SU9516 is a potent CDK2 inhibitor,with an IC50 of 22 nM,and also shows inhibitory effects on CDK1 and CDK4,with IC50s of 40,200 nM,respectively.
    (E/Z)-SU9516
  • HY-172128
    NUAK1-IN-2
    Inhibitor
    NUAK1-IN-2 (Compound 24) is a NUAK1 (IC50 of 3.162 nM) and CDK2/4/6 inhibitor. NUAK1-IN-2 can be used in cancer, neurodevelopmental disorders and Alzheimer's disease research.
    NUAK1-IN-2
  • HY-113670
    CLK1/2-IN-2
    Inhibitor
    CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC50 values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities[1].
    CLK1/2-IN-2
  • HY-16297R
    Abemaciclib methanesulfonate (Standard)
    Inhibitor
    Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib methanesulfonate (Standard)
  • HY-158170
    CDK7-IN-28
    Inhibitor
    CDK7-IN-28 (CDK7-1276) is a potent CDK7 inhibitor(IC50<5 nM). CDK7-IN-28 can inhibit proliferation of MDA-MB-468 cell line by blocking cell cycle and inhibiting DNA replication.
    CDK7-IN-28
  • HY-168162
    ZLC491
    Degrader
    ZLC491 is an orally active CDK12/13 PROTAC degrader. ZLC491 can be used in anticancer research.
    ZLC491
  • HY-RS02367
    Cdk16 Mouse Pre-designed siRNA Set A
    Inhibitor

    Cdk16 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk16 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk16 Mouse Pre-designed siRNA Set A
    Cdk16 Mouse Pre-designed siRNA Set A
  • HY-170507
    CDK-IN-16
    Inhibitor
    CDK-IN-16 (Compound 5g) is a CDK2/cyclin A2 inhibitor with an IC50 of 1.67 μM. CDK-IN-16 exhibits anticancer activity. The IC50 of CDK-IN-16 against the AGS cell line is 3.5 μM.
    CDK-IN-16
  • HY-149870
    PROTAC CDK9 degrader-8
    Inhibitor
    PROTAC CDK9 degrader-8 (compound 21) is a potent PROTAC CDK9 degrader with an IC50 value of 0.01 μM. PROTAC CDK9 degrader-8 can be used in research of cancer.
    PROTAC CDK9 degrader-8
  • HY-RS02373
    Cdk19 Rat Pre-designed siRNA Set A
    Inhibitor

    Cdk19 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk19 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk19 Rat Pre-designed siRNA Set A
    Cdk19 Rat Pre-designed siRNA Set A
  • HY-RS02362
    CDK14 Human Pre-designed siRNA Set A
    Inhibitor

    CDK14 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDK14 Human Pre-designed siRNA Set A
    CDK14 Human Pre-designed siRNA Set A
  • HY-147602
    CDK7-IN-17
    Inhibitor
    CDK7-IN-17 is a potent inhibitor of CDK7. CDK7-IN-17 is a pyrimidinyl derivative compound. CDK7-IN-17 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1).
    CDK7-IN-17
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.